Updated August 2026
BPC-157 for Tendon, Ligament & Muscle Injury: Research Dosage, Results, Safety & FDA Status
Research-status alert: BPC-157 is an experimental 15-amino-acid peptide. It is not FDA approved for any condition, has no approved human dosage, and has not been shown in a randomized published human trial to heal a tendon, ligament, or muscle injury. Most positive findings come from rats or laboratory cells. BPC-157 is also prohibited at all times in tested sport under the World Anti-Doping Agency (WADA) S0 category.
BPC-157 is better described as an experimental injury-repair peptide than a muscle-growth peptide. Rat studies report improved healing after experimentally created tendon, ligament, muscle, bone, and nerve injuries, with signals involving blood-vessel formation, fibroblast migration, collagen organization, nitric-oxide signaling, and cell survival. Those results have not established that BPC-157 builds muscle or accelerates sports-injury recovery in people.
Published human evidence consists of three very small, uncontrolled reports—knee injections, bladder-wall injections, and a two-person intravenous safety observation—plus registered trials without published efficacy results. No reliable human half-life, routine subcutaneous protocol, treatment duration, or long-term safety profile is established. Products sold online as “research use only” are not proven to contain the labeled identity, strength, purity, or sterility.
30-Second Summary
| Question | Evidence-based answer |
|---|---|
| What is it? | A synthetic 15-amino-acid peptide, sequence GEPPPGKPADDAGLV, originally described in gastric-protection research |
| Main research area | Tissue protection and repair, especially tendon, ligament, muscle-injury, gastrointestinal, vascular, and nerve models |
| Is it a muscle-growth peptide? | No proven anabolic or hypertrophy effect in humans; animal injury studies address restoration after damage, not muscle gain in healthy people |
| Administration studied | Multiple animal routes; limited human reports used intra-articular, bladder-wall, and IV administration |
| Human dosage | None established or FDA approved |
| Strongest evidence | Repeated positive findings in rodent injury models—not controlled human clinical evidence |
| Known side effects | Not adequately characterized; small human reports are far too limited to establish safety |
| FDA status | Not approved; FDA has identified compounding-related safety concerns |
| Sport status | Prohibited at all times under WADA S0 |
What Is BPC-157?
BPC-157—often expanded as “body protection compound 157”—is a synthetic pentadecapeptide with a molecular mass of approximately 1,419.5 Da. It is commonly described as a fragment related to a protective compound identified in gastric juice. That origin story does not mean commercial BPC-157 is a naturally extracted supplement or a normal replacement hormone; marketed material is synthetically manufactured.
Unlike growth hormone, IGF-1, or anabolic steroids, BPC-157 has no established endocrine receptor through which it predictably increases muscle protein synthesis. Its proposed effects are pleiotropic and incompletely mapped.
Does BPC-157 Build Muscle?
BPC-157 has not been shown to increase lean mass, muscle size, strength, or hypertrophy in healthy humans.
The “muscle growth” label usually comes from rodent studies in which muscle was cut, crushed, denervated, or otherwise severely injured. Treated animals sometimes recovered muscle-fiber diameter, force, or motor function better than controls. Restoring damaged tissue toward baseline is not the same outcome as building additional muscle in an uninjured athlete.
| Claim | What was actually measured | Appropriate conclusion |
|---|---|---|
| “Builds muscle” | No controlled human body-composition or hypertrophy trial | Unsupported |
| “Repairs torn muscle” | Improved histology and function in rat transection/crush models | Preclinical signal only |
| “Increases strength” | Some animal injury models showed better functional recovery | Not evidence of strength gain in healthy people |
| “Speeds recovery” | Animal healing outcomes; human efficacy remains unproven | Plausible research question, not established treatment effect |
| “Works at the injection site” | No human study has established site-specific subcutaneous targeting | Unsupported pharmacologic assumption |
BPC-157 Dosage Used in Human Research
There is no medically established BPC-157 dosage for muscle injury, tendon injury, ligament injury, pain, gastrointestinal disease, or any other indication. The exposures below document what specific investigators reported; they are not recommendations and cannot be converted into a self-treatment protocol.
Reported human research exposures — not dosing recommendations
| Study / registry | Population | Reported exposure | Route and duration | Study role |
|---|---|---|---|---|
| Lee & Padgett knee-pain chart review (2021) | 16 total; 12 BPC-157 alone | Later review reports a single 2–4 µg dose from a 2,000 µg/mL preparation; original report poorly detailed | One intra-articular injection | Exploratory retrospective treatment report |
| Lee et al. interstitial-cystitis chart review (2024) | 12 women | Ten 1 mg bladder-wall injections, 10 mg total, during one cystoscopic procedure | Intramural bladder injections once | Exploratory retrospective treatment report |
| Lee & Burgess IV pilot (2025) | 2 previously exposed healthy adults | 10 mg on day 1; 20 mg on day 2 | IV infusion in saline over one hour on each day | Short laboratory/vital-sign observation—not an efficacy dose study |
| PCO-02 / bepecin Phase 1 (NCT02637284) | Planned 42 healthy adults | Multiple oral cohorts registered; no results posted | Oral | Planned safety/pharmacokinetic study; registry status unknown |
| Acute grade II hamstring-strain Phase 2 (NCT07437547) | Planned 120 adults | Dose not publicly reported in accessible registry summary | Subcutaneous, once daily for 14 days, plus standardized rehabilitation | Randomized, double-blind, placebo-controlled efficacy trial; no results yet |
The radically different routes and amounts in these reports show why a single online “BPC-157 dose” is misleading. A bladder-wall procedure, an IV exposure study, a joint injection, an oral investigational product, and a subcutaneous trial are not interchangeable.
Is there a BPC-157 dose-escalation schedule?
No validated escalation schedule exists. The two-day 10 mg-to-20 mg IV sequence in two people was a tiny observational exposure protocol, not a titration plan. Common online regimens such as “200–500 micrograms daily,” dose-per-body-weight calculators, cycling schedules, and reconstitution instructions are not supported by an approved label or a published dose-ranging human efficacy trial.
For that reason, this page does not include a dose calculator, reconstitution calculator, injection map, or personalized schedule.
Human-evidence dashboard
Completed reports vs planned trials — do not merge denominators
- CompletedUncontrolled
Knee chart review
n=16
12 BPC-only · 4 combination
Subjective pain improvement; no placebo or imaging endpoint
- CompletedUncontrolled
Interstitial-cystitis chart review
n=12
12 women · bladder-wall injections
Uncontrolled; invasive co-intervention
- CompletedUncontrolled
IV pilot observation
n=2
10 mg day 1 · 20 mg day 2
Cannot estimate event rates or long-term risk
- PlannedUncontrolled
PCO-02 / Bepecin Phase 1
n=42planned
Oral safety/PK · NCT02637284
No results posted; registry status unknown
- PlannedControlled
Hamstring Phase 2
n=120planned
Grade II strain · NCT07437547
First registered controlled MSK efficacy study; no results yet
Never combine planned enrollment with exposed participants into a single “clinical evidence” total.
Routes Studied: Oral vs Injection vs Local Administration
Route–evidence matrix
Oral, injection, and local routes are not interchangeable
- Human evidence
- Phase 2 hamstring trial registered; no results
- Preclinical evidence
- Less central than IP/oral in older animal literature
- Not established
- Human PK, whether injection location matters, efficacy, AE rates
Animal pharmacokinetic research found that unchanged BPC-157 had an elimination half-life below 30 minutes after IV or IM administration. Mean IM bioavailability was approximately 14%–19% in rats and 45%–51% in beagle dogs. These are animal measurements, not a human half-life or proof that once-daily human dosing works.
BPC-157 Results by Tissue Type
The evidence concerns injured tissues recovering toward baseline in experimental models — not muscle gain in healthy athletes.
Tissue-recovery evidence map
Injured-tissue research — not a muscle-gain graphic
Tendon
Human: No tendon-specific controlled human trialClinical confidence: Very lowModels: Rat Achilles transection/detachment; cultured tendon fibroblasts
Reported signal: Greater load to failure, better organization; increased fibroblast migration/outgrowth
Translation warning: rodent healing rates, deliberately created injuries, and loading differ substantially from human sports tears or tendinopathy.
| Tissue | Models | Signal | Human evidence | Confidence |
|---|---|---|---|---|
| Muscle injury | Rat quadriceps transection, crush, myotendinous injury | Improved histology, fiber diameter, force/load measures, and motor function in some studies | No published controlled efficacy result | Very low |
| Tendon | Rat Achilles transection/detachment; cultured tendon fibroblasts | Greater load to failure, better organization; increased fibroblast migration/outgrowth | No tendon-specific controlled human trial | Very low |
| Ligament | Rat medial collateral ligament transection | Reduced instability and improved organization/function in reported models | None | Very low |
| Tendon-to-bone | Rat Achilles detachment/re-attachment | Improved tendon-to-bone healing, including under corticosteroid exposure | None | Very low |
| Bone | Rodent segmental-defect/fracture models | More organized bone formation in limited studies | None | Very low |
| Knee pain | Heterogeneous, unspecified human knee conditions | 11/12 BPC-only recipients reported improvement; 7/12 reportedly retained relief beyond six months | One uncontrolled retrospective report | Very low |
| Gastrointestinal | Rodent ulcer, fistula, bowel, liver, and drug-injury models | Cytoprotection and improved healing reported | No convincing published randomized therapeutic trial | Very low |
| Bladder / IC | Human symptom report after cystoscopic injections | 10/12 reported complete and 2/12 reported 80% symptom resolution | One uncontrolled retrospective report | Very low |
| Nerve / vascular | Rodent nerve, ischemia, thrombosis, and vessel-injury models | Neurofunctional and vascular-modulation signals | None | Very low |
Muscle-injury research
In rat quadriceps transection and gastrocnemius-crush experiments, BPC-157 was associated with better macroscopic healing, myofibril organization, muscle diameter, force-related measures, or walking/function indices. Some studies tested whether it could oppose healing impairment caused by corticosteroids.
These models deliberately create severe injury and then measure recovery. They do not answer whether BPC-157 increases muscle protein synthesis, improves resistance-training adaptations, or adds lean mass in people. The newly registered Phase 2 hamstring trial is designed to address a clinically relevant injury question using MRI and return-to-sport outcomes, but results are not yet available.
Tendon and ligament research
The best-known rat Achilles-tendon studies reported improved biomechanical and functional healing after complete transection or detachment. Laboratory work also found increased tendon-fibroblast outgrowth, survival, and migration. Rat medial-collateral-ligament models reported improved organization and stability.
Translation is uncertain because rodent healing rates, deliberately created injuries, drug exposure, loading, and rehabilitation differ substantially from human tendinopathy or sports tears. No published randomized human trial has shown faster tendon return to play, stronger repaired tissue, or lower reinjury risk.
Knee-pain result: what the 91.6% figure means
| Arm | Participants | Reported improvement | Critical limitations |
|---|---|---|---|
| BPC-157 only | 12 | 11/12 (91.6%) reported significant improvement | No placebo, randomization, blinding, standardized diagnosis, validated pain scale, imaging endpoint, or prespecified analysis |
| BPC-157 + thymosin beta-4 | 4 | 3/4 (75%) reported significant improvement | Extremely small combination arm; cannot isolate either compound’s effect |
The 91.6% figure is a responder fraction from a private-practice chart review, not a randomized efficacy rate. Placebo effects, natural symptom fluctuation, regression to the mean, concomitant care, and selection or recall bias could explain part or all of the observation. Pain improvement also does not prove cartilage, tendon, or ligament regeneration.
Current Human Clinical Evidence
Human evidence remains limited to uncontrolled chart reviews, a two-person IV observation, and registered trials without published results.
Injury-model study explorer
Primary studies and human reports
Achilles transection healing
Staresinic M et al. · 2003
TendonRatVarious preclinicalInjury model: Complete Achilles transection
Accelerated healing of transected rat Achilles tendon
Rodent model; not human tendinopathy
View source →Achilles detachment
Krivic A et al. · 2006
Tendon-to-boneRatVarious preclinicalInjury model: Achilles detachment
Improved tendon-to-bone healing measures
Rodent model under experimental loading
View source →Tendon fibroblast migration
Chang CH et al. · 2011
TendonCellIn vitroInjury model: Cultured tendon fibroblasts
Increased outgrowth, survival, and migration
Laboratory cell work; not patient outcomes
View source →Muscle healing
Pevec D et al. · 2010
MuscleRatVarious preclinicalInjury model: Muscle injury models
Improved muscle healing histology/function signals
Severe experimental injury ≠ human sports recovery
View source →Knee-pain chart review
Lee E, Padgett B · 2021
Knee painHumanIntra-articularInjury model: Heterogeneous knee pain
11/12 BPC-only reported significant improvement
Uncontrolled, subjective, no imaging endpoint
View source →Interstitial cystitis chart review
Lee E, Walker K, Ayadi AE · 2024
BladderHumanBladder-wallInjury model: Interstitial cystitis symptoms
10/12 complete and 2/12 80% symptom resolution reported
Tiny uncontrolled sample; invasive co-intervention
View source →IV pilot safety observation
Lee E, Burgess R · 2025
SafetyHumanIVInjury model: None (healthy adults)
No reported adverse effects over brief observation
n=2; cannot detect uncommon or delayed risk
View source →Hamstring Phase 2
ClinicalTrials.gov NCT07437547 · 2025
MuscleHumanSubcutaneousInjury model: MRI-confirmed grade II hamstring strain
Registered RCT; no results available
Cannot support a benefit claim until results publish
View source →Rat and dog pharmacokinetics
He L et al. · 2022
PKRat / DogIV / IMInjury model: PK / ADME
Unchanged peptide t½ <30 min IV/IM; IM F ≈14–19% rats, 45–51% dogs
Animal PK ≠ human half-life or dosing interval
View source →
Intra-articular injection for knee pain (2021)
Authors: Lee E, Padgett B · Design: Retrospective chart review, no control · Participants: 16; 12 BPC-157 alone and 4 plus thymosin beta-4 · Main result: 11/12 in the BPC-only group reported significant improvement · Key limitation: Very small, heterogeneous, uncontrolled and subjective; cannot demonstrate tissue healing or causality
Interstitial cystitis chart review (2024)
Authors: Lee E, Walker K, Ayadi AE · Dose: Ten 1 mg bladder-wall injections, 10 mg total · Main result: 10/12 reported complete and 2/12 reported 80% symptom resolution · Key limitation: Tiny uncontrolled sample, subjective outcome, invasive co-intervention
Intravenous pilot safety observation (2025)
Authors: Lee E, Burgess R · Dose: 10 mg IV day 1 and 20 mg IV day 2 · Main result: No reported adverse effects or material laboratory changes · Key limitation: Two pre-exposed people and very short follow-up cannot detect uncommon or delayed risk
Hamstring Phase 2 (NCT07437547)
Design: Phase 2, randomized, double-blind, placebo-controlled, with standardized rehabilitation · Planned: 120 adults with MRI-confirmed acute grade II hamstring strain · Co-primary endpoints: Time to unrestricted return to sport and change in MRI injury volume at day 14 · Current interpretation: First registered controlled human musculoskeletal efficacy study identified; no results available, so it cannot support a benefit claim.
BPC-157 Side Effects and Safety
“No adverse events reported” does not mean “proven safe.” A study of two people, for example, could easily miss an adverse event that occurs in 1 of 100, 1 of 1,000, or after months of exposure.
Safety: Simple View / Full Clinical Data
Overall conclusion
Promising preclinical biology with unproven clinical benefit and poorly characterized human risk. About 30 people across three uncontrolled reports — far too few to establish safety.
“No adverse events reported” ≠ proven safe
The IV pilot observed two pre-exposed people for a brief period. A study of that size could miss events that occur in 1 of 100 or after months of exposure.
FDA compounding concerns
FDA cites potential immunogenicity for some routes, peptide impurities/aggregation, and insufficient safety information for compounded or online products.
Product-quality and infection risk
Nonsterile or mislabeled injectable material can cause local or systemic harm independent of BPC-157’s pharmacology.
| Dataset | Exposed people | Reported AEs | Why insufficient |
|---|---|---|---|
| Knee chart review | 16 total | Inadequately characterized | Not designed for systematic safety detection |
| IC chart review | 12 | None reported | Small sample, no control, limited follow-up |
| IV pilot | 2 | None reported briefly | Cannot estimate rates or long-term risk |
| Randomized human safety DB | None identified | Not available | No robust denominator or surveillance |
Important known unknowns and potential risks
| Safety issue | Evidence status | Practical meaning |
|---|---|---|
| Immune reactions / immunogenicity | FDA identifies a potential risk for some routes | Repeated exposure to a peptide or aggregates/impurities may trigger immune responses; incidence unknown |
| Peptide impurities and aggregation | FDA cites API-characterization and impurity complexities | Active ingredient and degradants may not be consistently characterized in compounded or online products |
| Sterility, endotoxin, and infection | Product- and injection-related risk | Nonsterile or mislabeled injectable material can cause local or systemic harm |
| Angiogenesis | Seen in mechanistic/preclinical work | Pro-vascular signaling is part of the repair hypothesis but creates unresolved theoretical concern in cancer or pathologic vascular growth |
| Drug interactions | Not adequately studied | Interactions with anticoagulants, antiplatelets, cancer therapy, immunomodulators, or other peptides cannot be reliably predicted |
| Reproductive and developmental effects | No adequate human data | Safety in pregnancy, breastfeeding, fertility, or childhood is not established |
| Long-term exposure | No established human dataset | Delayed immune, proliferative, metabolic, or organ effects remain uncertain |
Seek urgent medical care for signs of a severe allergic reaction, infection, chest pain, shortness of breath, neurologic symptoms, or other serious symptoms after any injected or compounded product.
How BPC-157 May Work
In laboratory and animal experiments, BPC-157 appears to influence several parts of the injury response at once: formation and organization of small blood vessels, movement and survival of repair cells, collagen remodeling, inflammatory signaling, and communication between nitric oxide and vascular pathways. Researchers have not established one definitive human receptor or pathway that explains all claimed effects.
Mechanism visualization
Pleiotropic injury-response pathways — not proven regeneration
VEGF–VEGFR2–Akt–eNOS
Endothelial migration and angiogenic signaling
Cell / animal · no validated human biomarkerFAK–paxillin
Fibroblast adhesion, spreading, migration
Cell · no validated human biomarkerNitric-oxide system
Vascular tone, endothelial function, injury response
Animal · no validated human biomarkerGH receptor expression
Increased receptor expression in tendon fibroblasts
Cell · no validated human biomarkerCollagen / reticulin
More organized repair tissue in injury models
Animal · no validated human biomarkerInflammatory / oxidative
Reduced injury-associated markers in some models
Animal · no validated human biomarker
Mechanism data can explain why a trial is worth doing; they cannot substitute for a clinical trial.
BPC-157 vs Similar Recovery Options
| Option | Proposed role | Human MSK evidence | Regulatory status | Key distinction |
|---|---|---|---|---|
| BPC-157 | Experimental tissue-repair signaling | One uncontrolled knee-pain report; hamstring RCT pending | Not FDA approved; WADA prohibited | Most evidence is in rodents |
| TB-500 / thymosin-beta-4 fragments | Cell migration and repair signaling | No strong published evidence for common sports-injury use | Not FDA approved; prohibited in sport | “Wolverine stack” synergy is unproven |
| Platelet-rich plasma (PRP) | Autologous growth-factor concentrate | Condition-specific and mixed; multiple human trials exist | Procedure, not a universal FDA-approved injury drug | Evidence varies by tendon/joint and protocol |
| Progressive rehabilitation | Restore load tolerance, strength, and function | Substantial condition-specific clinical evidence | Standard care | Dosing is exercise/load based and diagnosis specific |
| HGH / IGF-1 axis drugs | Endocrine/anabolic signaling | Approved only for specific medical indications | Prescription drugs for defined indications | Mechanistically distinct from BPC-157 |
BPC-157 vs TB-500
BPC-157 and TB-500 are often sold together as a “Wolverine stack,” but there is no reliable human trial showing additive or synergistic healing. Combining two unapproved compounds makes attribution and safety monitoring harder. A 2026 rat Achilles study does not validate a human stack or self-injection protocol.
Evidence Quality
| Evidence type | Current strength | Why |
|---|---|---|
| Human randomized efficacy trials | Insufficient / results pending | A hamstring Phase 2 trial is registered; no result is available |
| Other human studies | Very low | About 30 people across three uncontrolled reports with different routes and indications |
| Animal musculoskeletal studies | Moderate preclinical consistency | Multiple positive injury models, but concentrated in rodents and overlapping research groups |
| Cell / mechanism studies | Hypothesis-supporting | Several plausible pathways; no single validated human target or surrogate |
| Human pharmacokinetics | Insufficient | Animal PK cannot define a human half-life or dosing interval |
| Human short-term safety | Very low | Tiny, poorly controlled datasets |
| Human long-term safety | Unknown | No adequate longitudinal study |
| FDA approval | None | No approved indication, formulation, route, or dose |
The overall conclusion is promising preclinical biology with unproven clinical benefit and poorly characterized human risk.
FDA, Compounding & Research Status
Is BPC-157 FDA approved? No. The FDA has not approved BPC-157 for injury recovery, muscle growth, pain, inflammatory bowel disease, interstitial cystitis, or any other use.
FDA has listed BPC-157 among bulk substances that may present significant safety risks when used in compounding, citing potential immunogenicity with some routes, peptide-related impurities and insufficient safety information.
In July 2026, FDA staff recommended against adding BPC-157 free base and acetate to the Section 503A Bulks List. The Pharmacy Compounding Advisory Committee then voted 8–6, with one abstention, to recommend inclusion. That advisory vote is nonbinding, does not itself change an FDA approval status, and does not mean BPC-157 was found safe or effective as a drug.
- Compounded BPC-157 is not FDA approved. Inclusion on a compounding list, if finalized, would address circumstances under which eligible pharmacies may compound; it would not provide an approved indication or verify clinical benefit.
- Banned in sport: WADA added BPC-157 to S0 in 2022; it remains prohibited at all times under the 2026 Prohibited List. Athletes are responsible for prohibited substances found in their samples.
Regulatory timeline
WADA prohibition, FDA concerns, and a nonbinding advisory vote
2022
WADA S0 listing
BPC-157 added to the S0 Non-Approved Substances category; prohibited at all times.
Sep 2023+
FDA compounding concerns
FDA identifies BPC-157 among bulk substances that may present significant safety risks (immunogenicity, impurities, insufficient safety information).
Jul 2026
FDA staff recommendation
FDA staff recommended against adding BPC-157 free base and acetate to the Section 503A Bulks List.
Jul 23, 2026
PCAC advisory vote
Pharmacy Compounding Advisory Committee voted 8–6 (1 abstention) to recommend inclusion. Nonbinding — not FDA approval.
Pending
Final FDA determination
Final FDA action on 503A listing should be checked before treating compounding eligibility as settled.
Advisory recommendations are nonbinding. Compounding eligibility is not FDA approval of safety or effectiveness.
Frequently Asked Questions
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid experimental peptide studied mainly in animal models of tissue injury and gastrointestinal protection.
Is BPC-157 a muscle-growth peptide?
No. BPC-157 has not been shown to increase human muscle mass or hypertrophy; positive muscle findings come from injured rodents recovering toward baseline.
What does BPC-157 do?
In preclinical models, BPC-157 influences angiogenesis, fibroblast migration, collagen organization, nitric-oxide signaling, and tissue-protection pathways, but its clinical effects in humans remain unproven.
What is the BPC-157 dosage?
There is no FDA-approved or evidence-based human BPC-157 dosage for any condition.
How often is BPC-157 used?
No clinically validated frequency exists. Once-daily schedules commonly advertised online should not be confused with approved dosing evidence.
Does BPC-157 need dose escalation?
No validated titration or escalation schedule has been established.
Is oral BPC-157 effective?
Human oral effectiveness has not been established; a registered oral Phase 1 study has no posted results.
Is injectable BPC-157 effective?
Injectable BPC-157 has not shown efficacy in a published randomized human trial. Small uncontrolled reports cannot establish benefit.
Does injecting near an injury make BPC-157 work locally?
No human evidence establishes that a subcutaneous injection near an injury selectively targets or heals that tissue.
How long does BPC-157 take to work?
No reliable human onset-of-action or healing timeline has been established.
What is BPC-157’s half-life?
The unchanged peptide’s elimination half-life was below 30 minutes in rats and beagle dogs after IV or IM dosing; a reliable human half-life has not been established.
What are BPC-157’s side effects?
The true side-effect profile is unknown. FDA highlights potential immune reactions, peptide impurities, and insufficient safety information, while injectable products also carry contamination and infection risks.
Can BPC-157 cause cancer?
There is no evidence proving that BPC-157 causes cancer in humans, but its pro-angiogenic biology creates an unresolved theoretical concern and long-term human cancer safety has not been studied adequately.
Does BPC-157 heal tendons or ligaments?
It improved healing measures in several rat tendon and ligament models, but human tendon or ligament healing has not been demonstrated in a controlled trial.
Does BPC-157 help knee pain?
One small uncontrolled chart review reported improvement in 11 of 12 BPC-only recipients, but the design cannot separate a drug effect from placebo, natural fluctuation, or other bias.
Is BPC-157 FDA approved?
No. BPC-157 is not FDA approved for any indication, route, formulation, or dosage.
Can a compounding pharmacy make BPC-157?
Federal compounding policy is under active review as of August 2026. An advisory vote does not equal final FDA action or drug approval; current FDA and state requirements must be checked.
Is BPC-157 prohibited for athletes?
Yes. BPC-157 is prohibited at all times under WADA’s S0 Non-Approved Substances category.
Is the BPC-157 and TB-500 “Wolverine stack” proven?
No. No reliable human trial establishes that this combination is effective or safer than either compound alone.
What is the best-supported approach to a tendon or muscle injury?
Diagnosis-specific care and progressive rehabilitation have far stronger human evidence; urgent evaluation is appropriate for major weakness, deformity, inability to bear weight, neurologic symptoms, fever, or suspected complete rupture.
References
FDA
Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety RisksCurrent FDA safety summary.
FDA
July 23–24, 2026 Pharmacy Compounding Advisory Committee meetingMeeting materials and regulatory review.
WADA
2026 Prohibited ListS0 Non-Approved Substances.
USADA
BPC-157: Experimental Peptide Creates Risk for AthletesAthlete advisory.
McGuire FP, et al.
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing2025.
Staresinic M, et al.
Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendonJ Orthop Res. 2003.
Chang CH, et al.
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration2011.
Lee E, Padgett B.
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain2021.
Lee E, Walker K, Ayadi AE.
BPC-157 for Interstitial Cystitis2024.
Lee E, Burgess R.
Safety of Intravenous BPC-157 in Humans: A Pilot Study2025.
He L, et al.
Pharmacokinetics, distribution, metabolism, and excretion of BPC157 in rats and dogsFront Pharmacol. 2022.
ClinicalTrials.gov
NCT07437547: BPC 157 for Acute Hamstring Muscle Strain RepairPhase 2 registry; no results yet.
Important Safety Information
BPC-157 is an experimental peptide with promising rodent injury-repair biology. It is not FDA approved, has no established human dosage, and has not shown efficacy in a published randomized human trial.
Human safety is poorly characterized. FDA highlights potential immunogenicity, peptide impurities, and insufficient safety information for compounding. Injectable research products also carry sterility and infection risks.
This page is an evidence reference for educational purposes. It is not a dosing, injection, or self-treatment guide.